CEL-SCI CORPORATION Income (Loss) from Continuing Operations, Per Diluted Share
CEL-SCI CORPORATION (CVM) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.87 per share for the 12-month period ending 2022-09-30, per its 10-K filed 2022-12-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2022-12-27
- CEL-SCI CORPORATION income (loss) from continuing operations, per diluted share for fiscal 2022 was -$0.87.
- CEL-SCI CORPORATION income (loss) from continuing operations, per diluted share for fiscal 2021 was -$0.93.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|
| 2022-09-30 | -$0.87 10-K · filed 2022-12-27 |
| 2021-09-30 | -$0.93 10-K · filed 2022-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |